Overcoming restrained lung trafficking by memory CD4+ T cells to prevent active tuberculosis in people living with HIV
通过记忆 CD4 T 细胞克服肺部运输受限,预防 HIV 感染者患活动性结核病
基本信息
- 批准号:10677889
- 负责人:
- 金额:$ 16.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-05 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AccelerationAutologousBenchmarkingBiological AssayBlood CirculationCD4 Lymphocyte CountCD4 Positive T LymphocytesCXC chemokine receptor 3CXCR3 geneCell AdhesionCell CountCell SeparationCellsChronicClonal ExpansionCoculture TechniquesCytoprotectionDevelopmentDiseaseExhibitsFrequenciesGoalsGrowthHIVHIV InfectionsHIV diagnosisHeterogeneityHumanImmunityImmunologicsImmunotherapyImpairmentIn VitroIndividualInfectionInfiltrationInflammationInflammatoryInterferonsInterleukin-12Interleukin-15LocationLongevityLungMacrophageMigration AssayModelingMusMycobacterium tuberculosisMycobacterium tuberculosis antigensPersonsPhenotypePositioning AttributeProductionQuality of lifeResearch PriorityResearch Project GrantsRiskSiteStructure of parenchyma of lungSurfaceSystemT-Cell ReceptorT-LymphocyteTestingTimeTuberculosisTuberculosis VaccinesUnited States National Institutes of HealthVaccinesVascular Endothelial CellVascular EndotheliumViraladhesion receptorchemokine receptorcytokinedisorder riskeffector T cellfractalkine receptorimprovedin vivolifetime riskmemory CD4 T lymphocytemigrationmonocytemouse modelnonhuman primatenovelpreventprogramsprotective efficacyreceptorreceptor expressionreceptor functionrestrainttraffickingvaccine developmentvaccine strategy
项目摘要
PROJECT SUMMARY / ABSTRACT
Tuberculosis (TB), caused by infection with Mycobacterium tuberculosis (Mtb), is a disease that kills 1.5
million people every year, and there is no reliable vaccine to prevent TB. CD4 T cells are critical for host
protection, acting through direct interaction with Mtb-infected cells via multiple effector mechanisms. People
living with HIV (PWH) who harbor latent Mtb infection (LTBI) have up to 20-fold greater risk of developing active
disease. The elevated risk of active TB in PWH persists despite maintaining CD4 T cell counts over 500 / uL and
effective viral suppression. However, an exact mechanism for the increased risk of TB among PWH with stable
CD4 counts is unclear. Given the efforts on T cell vaccines for TB, a key research priority is to determine which
specific attributes of memory CD4 T cells are critical to lowering the risk of TB in PWH. Identification of the unique
features of T cells from protected hosts would accelerate vaccine development and identify targets for host-
directed therapy. Recently, Mtb-specific CD4 T cells that express fractalkine receptor (CX3CR1) were shown to
contain potent effector functions, including robust IFNg secretion and cytolytic function, yet they are considered
non-protective since they are retained in lung microvasculature and are largely absent from lung parenchyma in
the mouse and non-human primate (NHP) models of TB. Interestingly, CX3CR1+ T cells are found with increased
frequency in PWH, possibly due to chronic inflammation. Our overarching hypothesis is that despite maintaining
stable total CD4 counts, the inflammatory state associated with HIV infection increases the proportion of
CX3CR1+ CD4 T cells specific for Mtb, among other effects, and impairs their lung parenchymal trafficking. This
project seeks to understand the trafficking and adhesion receptor expression and function of Mtb-specific
memory CD4 T cells, comparing those from HIV+ and HIV- individuals with LTBI. In Aim 1, we will use an
autologous ex vivo co-culture system to identify the memory CD4 T cells able to respond to Mtb-infected
macrophages and determine which trafficking and adhesion receptors they express. We further evaluate the
heterogeneity in T cell effector function and T cell antigen receptor (TCR) repertoire among the Mtb-specific CD4
T cells from HIV+ and HIV- individuals. In Aim 2, we will utilize a novel T cell migration assay to determine which
surface receptors are associated with the trafficking of memory CD4 T cells through vascular endothelium toward
Mtb-infected macrophages. For a vaccine to effectively prevent TB, it must elicit T cells that are able to mobilize
to the site of infection in the lung and recognize infected cells. Results from this study will determine the
differences in function and trafficking receptor expression between Mtb-specific CD4 T cells isolated from HIV-
and HIV+ individuals with LTBI, and the extent to which these differences correlate with T cell trafficking through
vascular endothelium. These results will provide benchmarks for TB vaccine development and will reveal targets
for receptor blockade that could improve T cell trafficking toward Mtb-infected cells.
项目总结/摘要
结核病(TB)是由结核分枝杆菌(Mtb)感染引起的疾病,
每年有200万人感染结核病,而且没有可靠的疫苗来预防结核病。CD 4 T细胞对宿主细胞的增殖至关重要。
保护,通过多种效应机制与Mtb感染的细胞直接相互作用起作用。人
携带潜伏性Mtb感染(LTBI)的HIV感染者(PWH)发生活动性结核病的风险高达20倍。
疾病尽管维持CD 4 T细胞计数超过500 / uL,但PWH中活动性TB的风险升高持续存在,
有效抑制病毒。然而,一个确切的机制,结核病的风险增加之间的PWH与稳定
CD 4计数不清楚。鉴于结核病T细胞疫苗的研究工作,一个关键的研究重点是确定
记忆性CD 4 T细胞的特定属性对于降低PWH中的TB风险至关重要。唯一标识
来自受保护宿主的T细胞的特征将加速疫苗的开发,并确定宿主的靶点。
定向治疗最近,表达Fractalkine受体(CX 3CR 1)的Mtb特异性CD 4 T细胞被证明是
含有有效的效应子功能,包括强大的IFNg分泌和细胞溶解功能,但它们被认为是
非保护性的,因为它们保留在肺微血管系统中,并且在肺实质中基本上不存在。
小鼠和非人灵长类动物(NHP)结核病模型。有趣的是,发现CX 3CR 1 + T细胞与CX 3CR 1 + T细胞相比,
PWH中的频率,可能是由于慢性炎症。我们的总体假设是,尽管维持
稳定的总CD 4计数,与HIV感染相关的炎症状态的比例增加,
对Mtb具有特异性的CX 3CR 1 + CD 4 T细胞,以及其他作用,并损害其肺实质运输。这
该项目旨在了解Mtb特异性的运输和粘附受体的表达和功能,
记忆性CD 4 T细胞,比较来自HIV+和HIV-个体的LTBI。在目标1中,我们将使用
自体离体共培养系统,以鉴定能够响应Mtb感染的记忆性CD 4 T细胞
巨噬细胞,并决定哪些运输和粘附受体,他们表达。我们进一步评估
Mtb特异性CD 4 + T细胞效应子功能和T细胞抗原受体(TCR)库的异质性
来自HIV+和HIV-个体的T细胞。在目标2中,我们将利用一种新的T细胞迁移试验来确定
表面受体与记忆性CD 4 T细胞通过血管内皮向血管内皮的运输有关。
结核杆菌感染的巨噬细胞。要使疫苗有效预防结核病,它必须引发能够动员的T细胞,
到达肺部感染部位并识别感染细胞。这项研究的结果将决定
分离自HIV-1的Mtb特异性CD 4 T细胞之间的功能和运输受体表达的差异。
以及这些差异与T细胞通过LTBI的运输相关的程度。
血管内皮这些结果将为结核病疫苗开发提供基准,并将揭示靶点
用于受体阻断,可以改善T细胞向Mtb感染细胞的运输。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stephen Matthew Carpenter其他文献
Stephen Matthew Carpenter的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stephen Matthew Carpenter', 18)}}的其他基金
Determining Protective Features of Human Memory T-cells to Inform Mycobacterium tuberculosis Vaccine Development
确定人类记忆 T 细胞的保护特征,为结核分枝杆菌疫苗的开发提供信息
- 批准号:
10682395 - 财政年份:2022
- 资助金额:
$ 16.1万 - 项目类别:
Overcoming restrained lung trafficking by memory CD4+ T cells to prevent active tuberculosis in people living with HIV
通过记忆 CD4 T 细胞克服肺部运输受限,预防 HIV 感染者患活动性结核病
- 批准号:
10546668 - 财政年份:2022
- 资助金额:
$ 16.1万 - 项目类别:
Determining Protective Features of Human Memory T-cells to Inform Mycobacterium tuberculosis Vaccine Development
确定人类记忆 T 细胞的保护特征,为结核分枝杆菌疫苗的开发提供信息
- 批准号:
10449464 - 财政年份:2022
- 资助金额:
$ 16.1万 - 项目类别:
相似海外基金
Phase I/II clinical trial of autologous T cell gene therapy to treat X-linked lymphoproliferative disease (XLP)
自体T细胞基因疗法治疗X连锁淋巴增殖性疾病(XLP)的I/II期临床试验
- 批准号:
MR/Y019458/1 - 财政年份:2024
- 资助金额:
$ 16.1万 - 项目类别:
Research Grant
Fabrication and Evaluation of Poly(glycerol sebacate) based small diameter vascular graft as a potent substitution for autologous vessels
基于聚(甘油癸二酸酯)的小直径血管移植物作为自体血管有效替代品的制造和评估
- 批准号:
2897580 - 财政年份:2023
- 资助金额:
$ 16.1万 - 项目类别:
Studentship
Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head
自体骨髓抽吸浓缩液治疗股骨头坏死
- 批准号:
10658324 - 财政年份:2023
- 资助金额:
$ 16.1万 - 项目类别:
Identifying multimodal biomarkers for autologous serum tears in the treatment of chronic postoperative ocular pain
识别治疗慢性术后眼痛的自体血清泪液的多模式生物标志物
- 批准号:
10794761 - 财政年份:2023
- 资助金额:
$ 16.1万 - 项目类别:
SBIR Phase II: An Injectable Protein Matrix to Enhance the Stability of Autologous Fat Grafts
SBIR II 期:可注射蛋白质基质,增强自体脂肪移植物的稳定性
- 批准号:
2304430 - 财政年份:2023
- 资助金额:
$ 16.1万 - 项目类别:
Cooperative Agreement
MICA: Strategy for heart repair in Duchenne Muscular Dystrophy (DMD) using genetically engineered autologous Mesoangioblasts
MICA:利用基因工程自体中成血管细胞修复杜氏肌营养不良症 (DMD) 的心脏的策略
- 批准号:
MR/X00466X/1 - 财政年份:2023
- 资助金额:
$ 16.1万 - 项目类别:
Fellowship
Application of Autologous Connective Tissue Sheets Created in Patients' Bodies to Pediatric Cardiac Valvuloplasty and Development of Dedicated Molds
患者体内自体结缔组织片在小儿心脏瓣膜成形术中的应用及专用模具的开发
- 批准号:
23K15543 - 财政年份:2023
- 资助金额:
$ 16.1万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
SBIR PHASE II, TOPIC 429: A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING
SBIR 第二阶段,主题 429:自体和同种异体细胞治疗制造的新范式
- 批准号:
10976161 - 财政年份:2023
- 资助金额:
$ 16.1万 - 项目类别:
Planning a phase I study of minor salivary gland derived autologous MSCs for prevention of long-term radiation induced xerostomia
计划对小唾液腺来源的自体 MSC 进行 I 期研究,以预防长期辐射引起的口干症
- 批准号:
10720234 - 财政年份:2023
- 资助金额:
$ 16.1万 - 项目类别:
HIV Reservoir and Gene Modified Cell Dynamics Following Autologous Stem Cell Transplantation
自体干细胞移植后的 HIV 储库和基因修饰细胞动力学
- 批准号:
10700521 - 财政年份:2023
- 资助金额:
$ 16.1万 - 项目类别: